Nâng cao quyết định điều trị
Ngay tại điểm chăm sóc

Vaping has emerged as a significant public health concern, with the WHO estimating over 100 million users globally in 2025, including approximately 15 million adolescents. Misleading marketing and social media advertisements have perpetuated misperceptions about the health risks of vaping, driving uptake particularly among adolescents and young adults. This paper reviews the current evidence, regulatory landscape, and clinical guidance, highlighting that regulatory interventions alone are insufficient, as the heterogeneity of regulatory environments across countries limits the applicability of blanket recommendations. A multipronged approach encompassing expanded pharmacotherapy options is needed. While no standardized vaping cessation guidelines exist, several countries are extrapolating from smoking cessation frameworks and expediting pharmacotherapy approvals, recognizing the urgency of addressing this growing epidemic.

Respiratory syncytial virus (RSV) remains a leading cause of hospitalisation and severe lower respiratory tract infection (LRTI) in infants worldwide. [Lancet 2022;399:2047-2064; Lancet 2017;390:946-958] In recent years, two immunoprophylactic strategies have become available to protect infants, namely maternal immunisation with the RSV prefusion F (RSVpreF) vaccine and passive immunisation of infants with the long-acting monoclonal antibody nirsevimab.

Theo kết quả phân tích MRI tăng cường tương phản động (DCE-MRI) của nghiên cứu MOSAIC giai đoạn IV, nhãn mở, Apremilast, chất ức chế phosphodiesterase-4 điều hòa miễn dịch đường uống, giúp giảm viêm ở các khớp riêng lẻ và viêm ngón (dactylitis) trên lâm sàng theo hình ảnh MRI ở bệnh nhân viêm khớp vảy nến (PsA).